Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Tandem Diabetes Care (TNDM) PT Lowered to $59 at Leerink Partners
November 7, 2024 5:57 AM ESTLeerink Partners analyst Mike Kratky lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $59.00 (from $62.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Despite posting another commanding topline beat (+9% vs. cons.), TNDM was bidding down high singledigits % post-market. We are... More
Tandem Diabetes (TNDM) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY24 Revenue Guidance
November 6, 2024 4:40 PM ESTTandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $244 million versus the consensus estimate of $223.66 million.
GUIDANCE:
Tandem Diabetes sees FY2024 revenue of $903-910 million, versus the consensus... More
